Treatment with Benlysta (belimumab) induces meaningful and long-lasting reductions in systemic lupus erythematosus (SLE) disease activity, helping a…
Articles by Ines Martins, PhD
Rheumatologists, researchers, and patients have joined forces on a global scale to better understand how COVID-19 affects people with…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with…
RemeGen has received $100 million in private financing to continue advancing RC18 (telitacicept), its lead treatment candidate for autoimmune…
Panniculitis — a group of conditions that causes painful bumps to appear under the skin — is a rare manifestation…
Omalizumab — a treatment already approved for allergic asthma and chronic hives — is well-tolerated and reduces disease activity in…
The U.S. Food and Drug Administration has granted fast track status to baricitinib for the treatment of systemic lupus erythematosus…
Zostavax, a live attenuated herpes zoster vaccine, is well-tolerated and causes an antibody response in patients with systemic lupus…
Systemic lupus erythematosus (SLE) patients with highly active disease responded well to treatment with atacicept at 150 mg each week…
Ustekinumab as an add-on to standard of care was seen to significantly increase the number of systemic lupus erythematosus (SLE)…